IL166063A0 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
IL166063A0
IL166063A0 IL16606304A IL16606304A IL166063A0 IL 166063 A0 IL166063 A0 IL 166063A0 IL 16606304 A IL16606304 A IL 16606304A IL 16606304 A IL16606304 A IL 16606304A IL 166063 A0 IL166063 A0 IL 166063A0
Authority
IL
Israel
Prior art keywords
antibodies
Prior art date
Application number
IL16606304A
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of IL166063A0 publication Critical patent/IL166063A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
IL16606304A 2002-07-01 2004-12-30 Antibodies and uses thereof IL166063A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903202A 2002-07-01 2002-07-01
PCT/US2003/020602 WO2004003166A2 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL166063A0 true IL166063A0 (en) 2006-01-15

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16606304A IL166063A0 (en) 2002-07-01 2004-12-30 Antibodies and uses thereof

Country Status (12)

Country Link
EP (1) EP1534332A4 (en)
JP (1) JP2005536199A (en)
KR (1) KR20060011925A (en)
CN (1) CN1678347A (en)
AU (1) AU2003263764A1 (en)
BR (1) BR0312483A (en)
CA (1) CA2491363A1 (en)
IL (1) IL166063A0 (en)
MX (1) MXPA05000272A (en)
PL (1) PL374439A1 (en)
RU (1) RU2005101621A (en)
WO (1) WO2004003166A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (en) 2003-09-05 2005-03-06 Gentium Spa FORMATIONS FOR ANTITUMORAL ACTION.
JP5710854B2 (en) * 2004-05-11 2015-04-30 アブゲノミクス コーペラティフ ユー．エー． T cell death-inducing epitope
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
ES2694239T3 (en) 2010-11-12 2018-12-19 Gentium S.R.L. Defibrottid for use in prophylaxis and / or treatment of Graft-versus-host disease (GVHD)
NZ619524A (en) 2011-06-13 2016-10-28 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies and uses thereof
IN2014DN10584A (en) 2012-06-22 2015-08-28 Gentium Spa
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
KR101896751B1 (en) * 2015-12-01 2018-10-04 주식회사 엘지화학 Thermoplastic resin, method for preparing the resin and thermoplastic resin composition comprising the resin
JP2021531007A (en) * 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Receptor for VISTA
CN111715409B (en) * 2020-07-01 2021-07-23 中南大学 Combined lead inhibitor of micro-fine particle galena and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347119A1 (en) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
WO2001073028A2 (en) * 2000-03-24 2001-10-04 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor

Also Published As

Publication number Publication date
AU2003263764A1 (en) 2004-01-19
BR0312483A (en) 2005-08-09
WO2004003166A2 (en) 2004-01-08
MXPA05000272A (en) 2005-09-20
JP2005536199A (en) 2005-12-02
CN1678347A (en) 2005-10-05
CA2491363A1 (en) 2004-01-08
RU2005101621A (en) 2005-11-20
KR20060011925A (en) 2006-02-06
WO2004003166A3 (en) 2005-03-10
PL374439A1 (en) 2005-10-17
EP1534332A4 (en) 2006-11-22
EP1534332A2 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
HK1248731A1 (en) Immunoglobulin variants and uses thereof
EP1551877A4 (en) Taci antibodies and uses thereof
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
EP1539941A4 (en) Adzymes and uses thereof
EP1494693A4 (en) Cripto-specific antibodies
IL172871A0 (en) Rg1 antibodies and uses thereof
PL375405A1 (en) Antibodies
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
IL172510A0 (en) Antibodies and uses thereof
IL166063A0 (en) Antibodies and uses thereof
EP1589033A4 (en) Antibody and use thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003249533A8 (en) Neoplasm specific antibodies and uses thereof
AU2003298739A8 (en) Intermedin and its uses
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0226878D0 (en) Antibodies
AU2003216442A8 (en) Enkurin and uses thereof
EP1627888A4 (en) Antibody and use thereof
GB0227080D0 (en) Antibodies and uses thereof
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof
EP1557430A4 (en) Antibody and utilization of the same
AU2003263751A8 (en) Novel proteins and their uses